Ischemic StrokeCOMPOCLOTNCT07384520
Thrombus Composition in Cerebral Infarctions: Study of Its Association With Plasma Biomarkers, Treatment Efficacy, Etiology and Prognosis.
An observational study of Ischemic Stroke and Cerebral Veinous Thrombosis, run by François Delvoye.
Trial summary
This study focuses on thrombi collected during mechanical thrombectomy procedures, as well as on plasma biomarkers analyzed concomitantly. The primary objective of the study is to investigate associations and correlations between, on the one hand, the composition of thrombi retrieved during thrombectomy and, on the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Stroke, Cerebral Veinous Thrombosis
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 12 Feb 2026to 30 May 2036
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Among patients treated at Liège University Hospital.
Who may be able to join
- Patients aged 18 years and older
- Presenting with cerebral infarction secondary to an arterial occlusion responsible for an ischemic stroke, or with cerebral venous thrombosis (CVT) having undergone a mechanical thrombectomy (MT) procedure
- Managed with mechanical thrombectomy
- Provision of free, informed, and explicit consent by the patient or their legal representative/next of kin (emergency inclusion procedure)
Who cannot join
- Patients under legal protection measures (e.g., guardianship or curatorship)
- Patients for whom the thrombectomy specimen cannot be retrieved or is not suitable for analysis (estimated at approximately 50% of patients undergoing MT)
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Composition du Thrombus Dans Les Infarctus cérébraux : étude du Lien Avec Avec Des Biomarqueurs Plasmatiques, l'efficacité du Traitement, l'étiologie et le Pronostic.
This study focuses on thrombi collected during mechanical thrombectomy procedures, as well as on plasma biomarkers analyzed concomitantly. The primary objective of the study is to investigate associations and correlations between, on the one hand, the composition of thrombi retrieved during thrombectomy and, on the other hand, plasma biomarkers, treatment response, etiology, and prognosis of ischemic stroke and cerebral venous thrombosis.
The secondary objectives of this study are to precisely characterize the biochemical composition of the thrombi (notably using techniques such as enzyme-linked immunosorbent assay [ELISA] following extraction of proteins contained within the thrombus), their histological structure (using standard histology with hematoxylin-eosin staining and immunohistochemistry), and their biological activity (in particular through in vitro assays assessing resistance to thrombolysis and the endothelial-adhesive or destructive properties of thrombi). Additional secondary objectives include testing new therapeutic methods for the lysis of thrombi collected by mechanical thrombectomy and establishing a link between thrombus transcriptomics and their confirmed etiology, particularly for thrombi initially described as having an embolic appearance and of undetermined etiology.
- Conditions
- Ischemic Stroke, Cerebral Veinous Thrombosis
- Keywords
- Mechanical thrombectomy, Thrombus
- Medical subject headings
- Ischemic Stroke, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patient treated with a thrombectomy | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diminution or increase of the NIHSS (National Institutes of Health Stroke Scale) score. The scale goes from 0 to 42, the higher, the more severe.
Measured: In the 24 hours after the thrombectomy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start12 Feb 2026 (estimated)
- Primary completion12 Feb 2036 (estimated)
- Study completion30 May 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- François Delvoye
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, François Delvoye, Centre Hospitalier Universitaire de Liege
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384520
- Sponsor's protocol ID
- 2025-286
- Acronym
- COMPOCLOT
- Status last verified
- Feb 2026
- First submitted
- 22 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Accessible upon request after publication
Publications
Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Vinuela F, Salamon N, Villablanca JP, Vinters HV, Marder VJ, Saver JL. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke. 2011 May;42(5):1237-43. doi: 10.1161/STROKEAHA.110.605576. Epub 2011 Mar 10.
PubMed 21393591
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Composition du Thrombus Dans Les Infarctus cérébraux : étude du Lien Avec Avec Des Biomarqueurs Plasmatiques, l'efficacité du Traitement, l'étiologie et le Pronostic.
- ClinicalTrials.gov ID
- NCT07384520
- Acronym / sponsor ID
- COMPOCLOT / 2025-286
- Conditions
- Ischemic Stroke, Cerebral Veinous Thrombosis
- Keywords
- Mechanical thrombectomy, Thrombus
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- François DelvoyeUniversity, hospital or other
- Study start
- 12 Feb 2026 (estimated)
- Primary completion
- 12 Feb 2036 (estimated)
- Study completion
- 30 May 2036 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study focuses on thrombi collected during mechanical thrombectomy procedures, as well as on plasma biomarkers analyzed concomitantly. The primary objective of the study is to investigate associations and correlations between, on the one hand, the composition of thrombi retrieved during thrombectomy and, on the other hand, plasma biomarkers, treatment response, etiology, and prognosis of ischemic stroke and cerebral venous thrombosis.
The secondary objectives of this study are to precisely characterize the biochemical composition of the thrombi (notably using techniques such as enzyme-linked immunosorbent assay [ELISA] following extraction of proteins contained within the thrombus), their histological structure (using standard histology with hematoxylin-eosin staining and immunohistochemistry), and their biological activity (in particular through in vitro assays assessing resistance to thrombolysis and the endothelial-adhesive or destructive properties of thrombi). Additional secondary objectives include testing new therapeutic methods for the lysis of thrombi collected by mechanical thrombectomy and establishing a link between thrombus transcriptomics and their confirmed etiology, particularly for thrombi initially described as having an embolic appearance and of undetermined etiology.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient treated with a thrombectomy | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Among patients treated at Liège University Hospital.
Key inclusion criteria (4 listed)
- Patients aged 18 years and older
- Presenting with cerebral infarction secondary to an arterial occlusion responsible for an ischemic stroke, or with cerebral venous thrombosis (CVT) having undergone a mechanical thrombectomy (MT) procedure
- Managed with mechanical thrombectomy
- Provision of free, informed, and explicit consent by the patient or their legal representative/next of kin (emergency inclusion procedure)
Key exclusion criteria (2 listed)
- Patients under legal protection measures (e.g., guardianship or curatorship)
- Patients for whom the thrombectomy specimen cannot be retrieved or is not suitable for analysis (estimated at approximately 50% of patients undergoing MT)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Diminution or increase of the NIHSS (National Institutes of Health Stroke Scale) score. The scale goes from 0 to 42, the higher, the more severe.
Time frame: In the 24 hours after the thrombectomy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Background: PubMed 21393591Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya AL, Zheng DD, Abolian AM, Kim D, Ali LK, Shah SH, Towfighi A, Ovbiagele B, Kidwell CS, Tateshima S, Jahan R, Duckwiler GR, Vinuela F, Salamon N, Villablanca JP, Vinters HV, Marder VJ, Saver JL. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke. 2011 May;42(5):1237-43. doi: 10.1161/STROKEAHA.110.605576. Epub 2011 Mar 10.
- Individual participant dataSharing planned: Undecided. Accessible upon request after publication
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Stroke and Cerebral Veinous Thrombosis, run by François Delvoye.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact François Delvoye, MD, PhD (04/3236630, fdelvoye@chuliege.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diminution or increase of the NIHSS (National Institutes of Health Stroke Scale) score. The scale goes from 0 to 42, the higher, the more severe. (time frame: In the 24 hours after the thrombectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07384520, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.